Nanobiotix (NASDAQ:NBTX) Stock Rating Reaffirmed by HC Wainwright

Nanobiotix (NASDAQ:NBTX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Friday, Zacks.com reports.

Nanobiotix Stock Up 1.2 %

Nanobiotix stock opened at $5.81 on Friday. Nanobiotix has a fifty-two week low of $1.75 and a fifty-two week high of $11.00. The firm’s fifty day moving average price is $6.26 and its 200-day moving average price is $6.54.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nanobiotix stock. Johnson & Johnson acquired a new stake in shares of Nanobiotix S.A. (NASDAQ:NBTX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 959,637 shares of the company’s stock, valued at approximately $8,397,000. Nanobiotix makes up about 3.1% of Johnson & Johnson’s holdings, making the stock its 9th largest holding. Johnson & Johnson owned about 2.65% of Nanobiotix as of its most recent SEC filing. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.